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Recent clinical and pre-clinical data demonstrate that adjuvant antimicrobial therapy is beneficial in cancer
treatment. There could be several reasons for this effect, which include treating cancer associated bacteria and
viruses, prophylaxis of post-chemotherapy infections due to immunosuppression, and antiproliferative effect of
certain antimicrobials. Targeting cancer associated viruses and bacteria with antimicrobial agents is currently used
for gastric, cervical, hematopoietic, liver and brain cancer. However this treatment is effective only in combination
with conventional therapies. Antimicrobials can also have a direct antiproliferative and cytotoxic effect, and can
cause apoptosis. Moreover, some antimicrobials are known to be helpful in overcoming side effects of drugs
commonly used in cancer treatment. Chemotherapy related bacteremia and neutropenia can be overcome by the
appropriately timed use of antimicrobials. This review summarizes the data on the effects of antivirals and
antibiotics on cancer treatment and describes their mechanisms.
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Major conventional cancer therapies include surgery,
chemotherapy, radiation therapy and symptom care.
Since 2010 cancer vaccines have been approved for use
against hepatitis B virus-associated liver cancer and
human papilloma virus-associated cancers. These ther-
apies have contributed to increased survival rates. Add-
itional targeted therapies have been approved by the
Food and Drug Administration (FDA) [1]. However, des-
pite recent advances in treatment methodologies, there
is still significant mortality rate associated with most
cancers. There is compelling data to support the clinical
use of antiviral and antibacterial agents in combination
with existing cancer therapies. Support for the use of
adjuvant antimicrobial therapy includes the existence
of cancer-associated viruses and bacteria, antimicrobial
prophylaxis following chemotherapy-associated immuno-
suppression and anti-proliferative activity of certain anti-
microbials. This review summarizes clinical data on the
use of antivirals and antibiotics in cancer therapy and* Correspondence: amussabekova@nu.edu.kz
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cancer treatment.Using antimicrobials to treat cancer-associated infections
More than 100 years have passed since it was first pro-
posed that infections may cause cancer [2], however the
role of viruses and bacteria in cancer is highly under-
rated among the cancer research community. Currently
identified oncogenic viruses include Hepatitis B virus
(HBV) and human papilloma virus (HPV), against which
global vaccination programs have been introduced.
Other oncogenic viruses include hepatitis C virus
(HCV), human T-lymphotropic virus (HTLV) and mem-
bers of Herpesviridae family, including Epstein-Barr
virus (EBV), Kaposi-sarcoma herpesvirus (KSHV) and
cytomegalovirus (CMV) (reviewed in [2,3]). Epidemio-
logical evidence also shows strong association between
certain bacteria (Helicobacter pylori, Salmonella typhi)
and cancer (reviewed in [4]). The roles and/or mechan-
isms of many other pathogens (polyomavirus, JC and BK
polyomaviruses, Chlamydia spp., Mycoplasma spp., Pro-
pionibacterium acnes, Streptococcus anginosus and
other) are still unknown. Growing evidence that infec-
tious agents are factors in tumorogenesis supports the
use of antimicrobial therapy in certain pathogen-td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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studies which demonstrate the use and efficacy of anti-
microbial adjuvant therapy.
Hepatocellular carcinomas
Up to 80% of hepatocellular carcinomas (HCC) are asso-
ciated with chronic HBV and HCV infections. This sug-
gests that almost 500,000 deaths could be prevented
annually by antiviral therapies. Clinical data show that
vaccination against HBV and antiviral therapy against
HCV can slow down the progression of liver disease
(reviewed in [5]). However, antiviral efficacy is signifi-
cantly better in patients during early stages of infection.
It was shown [6] that oral antiviral therapy reduces the
risk of hepatocellular carcinoma only in patients without
cirrhosis, but could not protect patients with chronic
infection.
Brain tumors
One of the members of Herpesviridae family, CMV is
considered an important therapeutic target for treating
brain tumors [7]. Human CMV (HCMV) has been
shown to induce the expression of COX-2, growth factor
for tumor cells. Many tumors express COX-2, moreover,
direct or indirect inhibition have been shown useful in
treating cancers. The HCMV protein US28 induces
COX-2 and Wnt target gene expression, which leads to
accumulation of β-catenin thereby increasing prolifera-
tion. HCMV is commonly associated with brain tumor
as it was present in human medulloblastoma cell lines,
and HCMV proteins were expressed in human brain
tumors [7]. A combination of ganciclovir (an antiviral
drug) and celecoxib (COX-2 inhibitor) reduced the pro-
liferative capacity of HCMV positive cell lines but had
no effect on HCMV negative medulloblastoma cells.
This drug combination significantly reduced tumor
growth in vitro. Use of the same combination of drugs
in murine model with HCMV-positive cancer cells led
to a 72% tumor reduction. These studies show that the
effect of the antiviral drug was HCMV specific.
Another promising antiviral drug for HCMV-associated
glioblastoma treatment is acyclovir, which inhibits HCMV
thymidine kinase [8]. It was reported that T-cell therapy
for patients with CMV-associated glioblastoma was bene-
ficial. They expanded CMV-specific T-cell population,
specific for viral pp65+ and IE1+ targets, inhibited CMV-
infected tumor cells [9].
Human herpes virus 8 associated cancers
KSHV (human herpes virus 8 [HHV8]) was shown to be
significantly associated with Kaposi’s sarcoma (KS), pri-
mary effusion lymphoma (PEL), and Castleman’s disease.
In preclinical studies, HHV-8 was sensitive to ganciclo-
vir, cidofovir and foscarnet but resistant to cyclovir inpreclinical studies. While several retrospective studies
show prophylactic usefulness of ganciclovir or foscarnet
against KS in patients with AIDS, other studies did not
demonstrate the same results. The role of antivirals in
therapies for Kaposi’s sarcoma is inconclusive due to the
lack of clinical follow-up and small number of patients
in these studies [10-12]. Tumor cell line models for PEL
can be targeted for apoptosis by inducing the activation
of latent HHV-8 infection. In this case, valproate was
used to trigger lytic replication of the virus, whereas
antiviral drugs were used to effectively control the acti-
vated virus. Further studies would prove useful to inves-
tigate whether the combination of valproate and
antiviral agents will be beneficial in a clinical setting.
Another severe lympho-proliferative complication in
HIV positive patients is Castleman’s disease. Ganciclovir
improved outcomes in three HHV-8 and HIV-positive
patients with Castleman’s disease and decreased HHV-8
DNA levels [13].
Nasopharyngeal carcinoma
Nasopharengeal carcinoma (NPC) is associated with sev-
eral viruses, such as HPV and EBV. The latter was ranked
as a group 1 carcinogenic agent by the International
Agency for Research Cancer [14]. It was found that [15]
found that cidofovir injected into tumor sites inhibited
tumor growth and EBV. In addition, as reviewed in [16],
cidofovir decreased tumor size and induced apoptosis
in HPV-infected nasopharyngeal carcinoma xenografts
of athymic mice. EBV DNA was detectable in more
than 90% of plasma samples from patients with NPC,
compared to 7% in healthy control patients. In addition,
it was shown that EBV DNA levels can be used to predict
clinical outcomes of the treatment in NPC patients. Al-
though NPC is associated with infection additional
clinical data should be acquired in order to determine
if NPC can be prevented and/or treated using other
antiviral therapies.
Hematopoietic cancers
Viral infections with HCV, EBV and human T-cell lym-
photropic virus type I -HTLV1 are associated with
hematopoietic cancers. There are several clinical studies
showing that zidovudine treatment, in combination with
interferon α (IFN-α), targets EBV in lymphoma cells
[16,17] and HTLV1 in adult T-cell leukemia-lymphoma
[18], leading to tumor inhibition. Interestingly, zidovu-
dine alone has poor antitumor activity because it is a
poor substrate for mammalian DNA polymerases. How-
ever, when used in combination with inhibitors of de
novo synthesis of thymidylate (e.g. MTX, IFN) it can
have cytotoxic effect against tumors. The direct cyto-
toxic effect of zidovudine and IFN were not found in
in vitro studies with HTLV1 positive cells. These results,
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HTLV1 replication, and transformation of healthy lym-
phocytes by HTLV1 in vitro, suggest a direct anti-viral
activity of this drug during treatment of adult T-cell
leukemia. Moreover, there is some evidence of direct
antiviral effect of IFN alone, against HTLV1 [19]. Treat-
ing EBV infection in central nervous system lymphoma
was successful in some cases, where a combination of
rituximab (an anti-CD20 monoclonal antibody) and anti-
viral drugs were used [18-20]. Full remission of acute
lymphoblastic leukemia after HCV-targeted treatment
with the combination of peginterferon α 2a and ribavirin
was shown in the clinical case was reported [21].Cancers associated with bacteria
As reviewed by [4], infections caused by several bacteria
(e.g. Bartonella spp., Lawsonia intracellularis and Citro-
bacterrodentium) can induce cellular proliferation that
can be reversed by antibiotic treatment. Antibiotic ther-
apy is common practice in mucosa associated lymphoid
tissue (MALT) lymphoma, gastric cancers and cervical
cancers. Population study on cervical cancer by Tamim
et. al [22] has shown the association of cancer develop-
ment with a Neisseria gonorrhoeae and Chlamydia tra-
chomatis infections and exposure to antibiotics up to 15
years in the past was associated with a decreased risk of
cervical cancer development.
Helicobacter pylori is a well-recognized agent involved
in gastric MALT lymphomas and gastric carcinomas
[23,24] and is increasingly associated with eye cancer,
breast cancer, and lung cancer [22]. The FDA and World
Health Organization (WHO) recommend the use of a
combined therapy to treat Helicobacter pylori infection:
amoxicillin and clarithromycin together with proton
pump blockers such as omeprazole/lanzoprazole and
muco-protectants (e.g. Sucralfate) [25]. Elimination of
bacterial infection leads to partial or complete remission
of MALT lymphoma in 60−80% of patients [23]. A re-
view of 24 studies showed complete remission of MALT
lymphoma in 35−100% of patients [26]. Thus, antibiotic
therapy is recommended as an affordable and safe first
line treatment, especially in low-grade MALT lymph-
omas, while oncologic therapies are recommended
for patients not responding to antibiotic therapy [26].
Similarly, Chlamydia psitacii eradication has been
recommended instead of more aggressive treatment regi-
mens for treatment of MALT-type eye cancers [22].
Overall, it can be concluded that in the cancers
which are strongly associated with infectious pathogens,
antimicrobial therapy shows promising results. How-
ever, almost always it is helpful only in combination
with existing chemotherapies and immunomodulatory
substances.Antimicrobials used as anti-proliferative and
cytotoxic agents
In addition to the proposed use of antiviral and anti-
biotic agents in treatment of cancers associated with
infections, these agents were reported to have direct
cytostatic and cytotoxic activities in cancer (both in vitro
and in vivo). Antiproliferative and cytotoxic effects
of selected antivirals and antibiotics are shown in Table 1.
Examples of the mechanisms by which some anti-
virals and antibiotics can cause apoptosis are shown in
Figure 1.Antivirals used as anti-proliferative and cytotoxic agents
Many antiviral agents were reported to have anti-
proliferative and proapoptotic activity in various cancers
through inhibition of transcriptional factors, inhibition
or activation of human DNA polymerase, suppression of
telomerase activity, increases in radiosensitivity and
downregulation of angiogenic genes. It was found that
certain antiviral agents can target translation initiation
factors. eIF4E, a eukaryotic translation initiation factor,
which is elevated in 30% of cancers, binds 7-methyl
guanosine cap on mRNA enhancing nuclear RNA trans-
port and translation. Treatment with the broad spectrum
antiviral agent ribavirin was beneficial in poor prognosis
acute myeloid leukemia [27]. Ribavirin relocalizes eIf4E
to the cytoplasm. By competing with binding of eIF4E
with mRNA and disrupting structure of eIF4E, ribavirin
reduces oncogene (cyclin D1 and NBS1) levels [27,28].
eIF4E is also known to regulate the expression of such
important molecules in cancer development as vascular
endothelial growth factor (VEGF), survivin, c-myc [29].
Ribavirin also inhibited eIF4E-associated transformation
of cells in vitro and eIF4E-dependent squamous cell car-
cinoma of human in in vivo mouse model [28]. In a
similar study, ribavirin inhibited cell proliferation,
reduced expression of eIF4E in breast cancer cell line
[29]. Ribavirin also modulates immunity and targets in-
osine monophosphate dehydrogenase, enzyme in guano-
sine biosynthesis pathway which may be an alternative
explanation of its antiproliferative activity [35].
It is known that inhibition of T-regulatory cells (Treg)
results in improved cancer immunotherapy [36]. Glio-
blastomas are characterized by a mild state of systemic
immunosuppression. Together with its potential use in
glioblastoma treatment due to its ability to inhibit HCMV
thymidine kinase another mechanism by which acyclovir
could be used in cancer therapy is by Treg inhibition in
glioblastomas. It has been shown that acyclovir has an
inhibitory activity on indoleamine 2,3-dioxygenase, and
thereby could inhibit Treg function. Given the short sur-
vival time of patients with glioblastoma together with























Figure 1 Schematic representation of the effect of antivirals and antibiotics on apoptosis.
Table 1 Antiproliferative and cytotoxic effect of selected antivirals and antibiotics
Anti-microbial Target and its function Mechanism Shown in References
Ribavirin Eukaryotic translation initiation factor: eIF4E;
Enhanced mRNA transport and translation of
cyclin D1, survivin, c-myc, VEGF and etc.
Ribavirin binds to eIF4E with high affinity and
competes with its binding to mRNA; selectively
disrupts eIF4E subcellular organization and
therefore transport and translation of mRNAs
which are post-transcriptionally regulated by
eIF4E leading to decreased levels of oncogenes






Acyclovir indoleamine 2,3-dioxygenase (IDO);
enhances activity of Treg while Treg inhibits
immunity in glioblastomas
Acyclovir could decrease Treg function in
glioblastoma and could potentially be used as






HSP-90 promotes survival of tumor cell,
induces their growth and metastasis even
when there are no growth factors via
continued protein translation and cellular
proliferation; Its client proteins include:
KIT, AKT, CDK4, telomerase, Bcl-2, MMP2
and others.
Inhibition of HSP90 leads to decreased level
and activity of its client protein protooncogene
KIT and downstream signaling molecules AKT
and STAT3
HMC-1 cells derived
from a patient with
mast cell leukemia
[30,31]
Hsp90 inhibition by 17-AAG leads to decreased
proliferation and viability and increased





Clioquinol Acts as metal ionophore Probably increases metal concentration in
mitochondria and induces release of
cytochrome c leading to apoptosis
DHL-4, A2780, SiHa






VEGF, EGF, FGF, PDGF and their receptors
are important in angiogenesis
Diphosphate derivatives of PMEG and PMEDAP
inhibit DNA polymerase and activity of human
telomerase in vitro. DNA damage could affect
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treatment [8].
Cancer cells are characterized by increased telomerase
activity and telomerase inhibition leads to apoptosis
[37]. Zidovudine, an antiviral drug, was shown to sup-
press telomerase activity and increase the radiosensitivity
in glioma cells [38]. In another study, zidovudine as an
inducer mitochondrial dysfunction was shown to en-
hance cytotoxic activity of cisplastin via thiol metabolism
and oxidative stress in cells of head and neck cancer.
Zidovudine’s effect against cancer cells was due to
causing increased oxidative stress [39]. The viability
of human hepatoma cells was significantly decreased
after four week treatment with zidovudine (AZT) and one
week recovery. This was due to a delay of cell cycle
progression, induction of apoptosis and decreased tel-
omerase activity [40].
Diphosphate forms of PMEG (9-[2-(phosphonomethoxy)
ethyl]-guanine) and PMEDAP (9-[2-(phosphonomethoxy)
ethyl]-2,6-diaminopurine) have ability to inhibit human
telomerase activity in vitro. Another prospective use of anti-
virals lies in their ability to inhibit angiogenic genes. For in-
stance, in rats with SD-lymphoma PMEG and PMEDAP
were able to modulate expression of angiogenic genes.
PMEG was more potent in downregulation of expression of
such genes as epidermal growth factor (EGF), fibroblast
growth factor (FGF), platelet-derived growth factor (PDGF),
vascular endothelial growth factor (VEGF) and their recep-
tors while PMEDAP affected mainly expression of VEGF
and its receptor [34].
Antibiotics used as anti-proliferative and cytotoxic agents
Anthracycline antibiotics such as doxorubicin and dau-
nomycin are widely used in cancer treatment in humans
[41]. Although the exact "antitumor activity of anthracy-
cline" is controversial, suggested mechanisms include:
intercalation into DNA, production of free radicals,
DNA binding and alkylation, DNA cross-linking, inhib-
ition of topoisomerase II. However the amount of
doxorubicin used during some of the studies was supracli-
nical complicating the proposed mechanisms of antitumor
activity. Anthracyclines are also known to induce cardio-
myopathy [42]. Other classes of antibiotics are under
investigation for their potential application in cancer
treatment and mode of antiproliferative action is vari-
ous in different classes of antibiotics.
After discovering that some metal chelators such as
desferrioxamin can inhibit tumor growth, other antibio-
tics chelators were investigated for their potential antitu-
mor abilities. Clioquinol as a chelator of copper and zinc
was hypothesized to inhibit superoxide dismutase-1, a
potential tumor target, which uses these metals as
cofactors. Clioquinol treatment led to apoptosis via
caspase activation in human tumor cell lines. However,cytotoxicity of this agent was not due to its chelating abil-
ities because addition of copper and zinc enhanced its
antitumor effect but this antibiotic had an ability to trans-
port metals inside the cell and act as a transition metal
ionophore instead. Increased concentrations of metals in
mitochondria, for example, can lead to Cytochrome c re-
lease leading to apoptosis [33].
A number of thiazole antibiotics were revealed to have
antiproliferative activity by inhibiting transcription fac-
tors. It was shown in in vitro experiments that thiazole
antibiotics Siomycin A and thiostrepton inhibit tran-
scriptional activity of Forkhead box M1 or FoxM1. FoxM1
is an oncogenic transcription factor and considered
to be a promising target in tumor treatment since it
is overexpressed in many types of human tumors such as
hepatocellular carcinomas, pancreatic carcinomas, breast
cancers, non-small cell lung carcinomas. Particularly these
antibiotics had antiproliferative activity and can induce
apoptosis [43]. This family of antibiotics is known to bind
to the large ribosomal subunit and inhibit protein synthe-
sis in prokaryotes. Furthermore thiazole antibiotics had
anti-proliferative activity in vivo in xenograft model of
human breast cancer [44].
A number of fluoroquinolones were shown to have
antitumor activity as well [45]. In bacterial cells they in-
hibit topoisomerase type II/DNA gyrase [46] and until
recently their effect on mammalian cells was unknown.
One of fluoroquinolones, ciprofloxacin, inhibited the
growth of bladder transitional cell carcinoma, colon can-
cer and prostate cancer cells [45]. It induced apoptosis
and inhibited proliferation of human colorectal carcin-
oma cells presumably by blocking mitochondrial DNA
synthesis. Ciprofloxacin had no such an effect on hepa-
toma cells [46]. Another member of this family of
antibiotics moxifloxacin had an ability to inhibit acti-
vation of NFkB, mitogen-activated protein kinase and
interleukin-8 synthesis. Moxifloxacin enhances etopi-
sode’s (VP-16) antitumor effect in tumor cells (THP-1
and Jurkat) via inhibition of topoisomerase II. Moreover,
moxifloxacin overcomes one of the drawbacks of using
etopisode in cancer treatment by it inhibiting the re-
lease of proinflammatory cytokines [45]. Ciprofloxacin
induced apoptosis and reduced proliferation of prostate
cancer cells whereas non-tumorigenic prostate epithe-
lial cells were not affected. The mechanism of cipro-
floxacin activity is associated Bcl-2- associated X protein
(Bax) insertion into mitochondrial membrane, increased
ratio of Bax-to-Bcl-2 and cell cycle arrest at S-G2/M
phase [47].
Some members of benzoquinanone ansamycin such as
geldanamycin and its derivatives (17-AAG, 17-DMAG)
cause degradation of tumorigenic proteins by binding to
heat shock protein 90 (Hsp90) [30]. Hsp90 promotes sur-
vival of tumor cell, induces their growth and metastatsis
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tein translation and cellular proliferation. Client proteins
of Hsp90 important in cancer which include various
transcription factors, kinases and etc are reviewed
elsewhere [31]. 17-AAG can result in destabilization of
Hsp-dependent kinases that are important in cancer de-
velopment by inhibiting Hsp90 [30]. The geldanamycin
derivative,17-AAG had antiproliferative and cytotoxic ac-
tivity human oesophageal cancer cell lines and increased
their radiosensitization [32].
Antimicrobial prophylaxis prior and after cancer therapy
Chemotherapy-induced neutropenia and bacteremia
Patients suffering from malignant tumors often develop
chemotherapy-induced neutropenia leading to immuno-
suppression and bacterial, viral and fungal infections. Ten
to fifty percent of patients with solid tumors and
80% of those with hematologic malignancies will de-
velop fever associated with neutropenia during more than
one chemotherapy cycle [48]. Infections in patients suffer-
ing from hematological malignancies are a major problem.
Malignancies by themselves, or by virtue of their thera-
peutic strategies (chemotherapy, radiation, hematopoietic
stem cell transplant [HSCT]), put patients at risk for
infections. Some infections are associated with spe-
cific predisposing factors in patients with hematological
malignancies, such as neutropenia with insufficient
phagocytosis, abnormal T-cells with cellular immune
dysfunction, abnormal B-cells with humoral immune
dysfunction and chemotherapy-related immune sup-
pression [49]. Abnormal T-cells are associated with
higher risks for Listeria, Legionella, Salmonella, Nocardia,
Pneumocytis, Toxoplasma, Cryptosporidium, Mycobac-
teria, Candida, Cryptococcus, Histoplasma, and HHV
infections. Hematological patients with abnormal B cells
with humoral immune dysfunction are at increased risk of
sinusitis, pneumonia, meningitis and sepsis [50].
Bacteremia was documented in about 10%-25% of fe-
brile neutropenia cases [51]. Common infection sites in-
clude tissue-based infection of the intestinal tract, lung,
and skin. Therefore, initiation of antibiotic therapy after
chemotherapy is vital for preventing mortality due to
infections [52]. During the initial development and prac-
tical implementation of chemotherapy in 1960s and 70s,
Gram-negative pathogens predominated following chemo-
therapy treatments. Currently Gram-positive infections
are becoming more common in cancer patients. The
latter include coagulase-negative staphylococci, such as
Staphylococcus aureus, including methicillin-resistant
strains, Enterococcus species, including vancomycin-
resistant strains S.viridans streptococci, Streptococcus
pneumoniae, Streptococcus pyogenes. Common Gram-
negative bacteria include Escherichia coli, Klebsiella
species, Enterobacterspecies, Pseudomonas aeruginosa,Citrobacterspecies, Acinetobacterspecies, Stenotrophomonas
maltophilia [53,54]. The increasing number of Gram-
positive infections is probably due to the increased use of
indwelling plastic venous catheters which allow the entry
of Gram-positive bacteria from the skin.
Drug-resistant Gram-negative infections are predomin-
ating in neutropenic patients [55-57]. Broad spectrum
beta-lactamase genes are often expressed by Klebsiella
species and E.coli strains, and result in β-lactam antibiotic
resistance [58,59]. Resistance among Gram-positive patho-
gens especially methicillin resistant Staphylococcus aureus
and vancomycin resistant enterococci have become more
common, accounting for about 40% [60,61].
Colony stimulating factors (CSFs) are used as a
prophylactic agent in cancer patients suffering from
chemotherapy-induced neutropenia. It has been demon-
strated [62] that administration of antibiotics such as levo-
floxacin, ciprofloxacin and norfloxacin with addition
to granulocyte CSF decreased the number of identifiable
infections in lung cancer patients. Preclinical data [63] has
shown that the administration of antibiotics such as
ciprofloxacin, trimethoprim-sulfamethaxazole, cafazolin
and nitrofurantoin, after transurethral resection of bladder
tumors could prevent seeding of cancer cells, as a result
decrease the rate of recurrence in a dose dependent man-
ner. Ciprofloxacin exhibit time- and dose dependent cyto-
toxicity against transitional carcinoma and significantly
enhance cytotoxic effect of doxorubicin [64].
Fungal infections prophylaxis
Patients with hematologic malignancies and hematopoietic
stem cell transplantation (HSCT) recipients represent
a population at high risk for invasive fungal disease.
Late fungal infection diagnoses are associated with se-
vere morbidity and high mortality of hematological
patients. In 2005, as a result of collaborations between
several groups, including the European Group for Blood
and Marrow Transplantation, the European Organization
for Treatment and Research of Cancer, the European
Leukemia Net and the Immuno-compromised Host
Society, the European Conference on Infections in
Leukemia (ECIL) was created. The main goal of ECIL
is to elaborate upon guidelines or recommendations
for the management of infections in hematology patients,
including information on antifungal prophylaxis in high-
risk hematology patients, empirical antifungal therap-
ies, and treatment strategies for invasive Candida and
Aspergillus infections.
Guidelines for primary antifungal prophylaxis are avail-
able [65,66]. In cases of allogeneic HSCT the ECIL-3
Working Group has proposed to provide phase-specific
guidelines for HSCT recipients such that fluconazole is
highly recommended in the initial phase, but only when
combined with a mold-directed diagnostic approach.
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chronic graft-versus-host disease (GVHD). However, the
working group recommended therapeutic drug monitor-
ing, especially in patients with intestinal GVHD. During
GVHD, fluconazole becomes less relevant because of the
high risk of mold disease. Voriconazole and itraconazole
prophylaxis has also been shown to be as effective as flu-
conazole for Candida prophylaxis in patients undergoing
allogeneic stem cell transplants [67-69]. According to pub-
lished data [67,68,70] the ECIL 3 recommends use of vori-
conazole in both phases of HSCT (initial neutropenia and
GVHD phases) with a provisional AI grading.
Viral infections prophylaxis
Agents against HSV such as acyclovir should be offered
to HSV-seropositive HSCT recipients [71] and patients
with acute leukemia [72] as a prophylaxis until recovery
of the white blood count or resolution of mucositis.
Prophylaxis can be extended for patients with frequent
recurrent HSV or GVHD infections and could last for
up to 1 year [73]. Other herpesvirus infections occur in
the post-HSCT setting, including infections due to cyto-
megalovirus and human herpesvirus 6.All cancer patients
should be immunized against influenza on a yearly basis,
despite the illusive vaccine efficacy, inactivated vaccine are
shown to yield adequate response in some patients treated
for solid malignancies [74,75]. However, live attenuated in-
fluenza vaccines should be avoided in patients receiving
chemotherapy cycles and during 6 months after the end of
therapy. It is was shown that influenza vaccination
responses may be best between chemotherapy cycles
(7 days after the last treatment) or 2 weeks before chemo-
therapy starts [75-77]. HSCT recipients usually respond
best to influenza vaccination if vaccinated at 6 months
after transplantation. If an exposure to influenza occurs,
5 days of post-exposure treatment with anti-influenza
antivirals (eg, oseltamivir or zanamivir) is recommended
for the neutropenic patient regardless of vaccination status
[78]. Patients with respiratory complaints, including cough
and nasal congestion or a pulmonary infiltrate noted on
chest radiograph during the peritransplant period, should
be evaluated by examination of nasopharyngeal swab or
washing specimens. The specimen can be tested by PCR,
direct antigen assay, or culture for respiratory viruses
(including influenza, parainfluenza, adenovirus, RSV, and
human metapneumovirus) [79]. Neutropenic patients
infected with respiratory viruses (including influenza,
parainfluenza, adenovirus, RSV, and human metapneumo-
virus) may be a febrile and may lack “classic” systemic
symptoms, such as myalgia [80]. Ribavirin has been used,
however there is no antiviral agent proven to be effective
against parainfluenza virus [81] and RSV pneumonia [82].
Monoclonal antibody (palivizumab) and RSV immuno-
globulin are not preventing or attenuating RSV upperrespiratory infection [83]. Cidofovir or ribavirin were used
for clinically significant adenovirus disease [84], however
there is no proven effective therapy against adenovirus.
Overall, chemotherapy-related immunosuppression
resulting mainly in inhibition of neutrophils and subse-
quent infections is a significant problem in cancer treat-
ment, where antimicrobial prophylaxis can be of a great
clinical significance.
Conclusion
Outcomes of cancer treatments depend on many factors,
many of which are still unknown. Frequent treatment
complications include viral, bacterial, and fungal infections,
which have roles in the etiology, affect the outcome of the
treatment, and may arise as a side effect of the therapy.
With development of many classes of antimicrobials,
microbial related carcinogenesis and therapy complications
are the most preventable. However, there are not many
studies that have investigated the value of adjuvant anti-
microbial therapy in the course of cancer treatment.
Antimicrobial agents can benefit cancer patients by kill-
ing oncogenic-related microorganisms, by protecting from
recurring immunosuppression-induced infection, and by
their direct antiproliferative/cytotoxic effects. Different
mechanisms are involved in antiproliferative effects of
antimicrobials, such as targeting translation initiation fac-
tors, degrading tumorigenic proteins by binding to heat
shock proteins involved in their folding, having antiangio-
genic effects, inhibiting topoisomerases, destabilization of
mitochondria and other effects causing apoptosis. More-
over, antimicrobials could potentially decrease some side
effects of currently used therapies against cancer. These
include inhibition of proinflammatory cytokine release
and the induction of cytotoxic activities by conventional
chemotherapy drugs. However, the current administration
of antivirals and antibiotics in cancer therapy should only
be in combination with anticancer drugs to increase the
effectiveness of current therapies.
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